Planned Parenthood’s involvement in the cross-sex hormone business for those with gender dysphoria has increased at a concerning rate in recent years.

Since beginning these drugs, referred to as “gender-affirming care” in 2005, 41 of its 49 regional branches were offering such services by 2022. Notably, between 2020 and 2022, hormone therapy services increased by 125%. Data shows a jump from 17,036 visits in 2020 to 38,337 in 2022.

Planned Parenthood Mar Monte, operating clinics in central California and parts of Nevada, reported a significant increase in “gender-affirming care” visits from 1,041 in 2020 to 4,378 in 2022, and then to 9,288 in 2023. These clinics provide hormone therapy for patients aged 18 and older, and also for 16 to 17-year-olds with parental consent.

Similarly, Planned Parenthood California Central Coast’s annual report shows 299 initial and follow-up visits for cross-sex hormones for the fiscal year 2019-2020 and 746 in the 2021-2022 fiscal year….

From California Family Council